Source comparison
Sermorelin vs. CJC-1295 vs. Tesamorelin Comparison
Three distinct GHRH analogues dominate the research peptide landscape: Sermorelin, CJC-1295, and Tesamorelin. While all function as GHRH agonists, critical pharmacological differences distinguish them. Sermorelin comprises amino acids 1-29 of native GHRH. It e
This comparison does not assign a generated winner or score.
- Three distinct GHRH analogues dominate the research peptide landscape: Sermorelin, CJC-1295, and Tesamorelin. While all function as GHRH agonists, critical pharmacological differences distinguish them.
- Sermorelin comprises amino acids 1-29 of native GHRH. It exhibits excellent receptor affinity but undergoes rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), producing a brief circulating half-life of 5-7 minutes.
- CJC-1295 (tetrasubstituted) represents a synthetic GHRH analogue with extended circulating half-life (approximately 30-38 minutes) achieved through structural modifications that resist DPP-4 degradation. This extended half-life permits less frequent dosing protocols in research applications.
- Tesamorelin is a 44-amino acid peptide (GHRH analogue conjugated with albumin-binding domain) engineered for sustained circulating availability. Clinical research has employed Tesamorelin specifically for lipodystrophy and visceral adiposity research, particularly in HIV-associated metabolic complications.
- Research design considerations determine which compound is most appropriate: Sermorelin’s brief half-life suits investigations requiring acute GH stimulation dynamics; CJC-1295 permits study of sustained GH elevation without continuous dosing; Tesamorelin’s extended profile and clinical precedent provide advantages for longer-term investigation protocols.